Active	Status	Sponsor type	Region	Phase	Filter
17 Active 6 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oral, Elif A
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy	Active, not recruiting	4	10	US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalized Lipodystrophy	10/24	04/25
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)	Active, not recruiting	2	4	US	Metreleptin	University of Michigan, Amryt Pharma	Lipomatosis, Multiple Symmetrical	04/24	04/25
LEAP, NCT05088460: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)	Terminated	2	20	Europe, US, RoW	REGN4461, mibavademab, Matching Placebo	Regeneron Pharmaceuticals	Familial Partial Lipodystrophy, Metabolic Abnormalities	10/23	04/24
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)	Recruiting	N/A	240	US	EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham	GI Dynamics, Biostatistical Consulting, Inc.	Diabetes type2, Obesity	04/24	04/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes	Recruiting	N/A	320	Europe, US	Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)	Fractyl Health Inc.	Type 2 Diabetes	06/24	01/26
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry	Recruiting	N/A	100	Europe, US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalised Lipodystrophy, Partial Lipodystrophy	10/31	10/31
Kwon, Richard s
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)	Recruiting	N/A	240	US	EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham	GI Dynamics, Biostatistical Consulting, Inc.	Diabetes type2, Obesity	04/24	04/25
Law, Ryan
NCT06174805: AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE	Not yet recruiting	N/A	67	Europe, Canada, US, RoW	AXIOS(TM) Stent and Electrocautery Enhanced Delivery System	Boston Scientific Corporation	Gastric Outlet Obstruction	08/26	08/26
Schulman, Allison R
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)	Recruiting	N/A	240	US	EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham	GI Dynamics, Biostatistical Consulting, Inc.	Diabetes type2, Obesity	04/24	04/25
Krafton, Andrew T
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)	Recruiting	N/A	240	US	EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham	GI Dynamics, Biostatistical Consulting, Inc.	Diabetes type2, Obesity	04/24	04/25
Volk, Sarah
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)	Recruiting	N/A	240	US	EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham	GI Dynamics, Biostatistical Consulting, Inc.	Diabetes type2, Obesity	04/24	04/25